Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT04840602
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04817241
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT04810598
- Locations
- 🇺🇸
Orlando Clinical Research Ctr /ID# 224922, Orlando, Florida, United States
🇺🇸Acpru /Id# 243398, Grayslake, Illinois, United States
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT04812548
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT04801797
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Conditions
- Acute Biphenotypic LeukemiaMixed Phenotype Acute LeukemiaRelapsed Acute Myeloid LeukemiaRelapsed Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid LeukemiaRelapsed Acute Biphenotypic LeukemiaRelapsed Myeloid NeoplasmRefractory Acute Biphenotypic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRefractory Myeloid Neoplasm
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT04797767
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04790903
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
🇫🇷CHU Montpellier - Saint ELOI, Montpellier, France
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Paolo Ghia
- Target Recruit Count
- 30
- Registration Number
- NCT04790045
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.